Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients
Open Access
- 10 March 2003
- journal article
- Published by Wiley
- Vol. 55 (3) , 270-277
- https://doi.org/10.1046/j.1365-2125.2003.01767.x
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Explaining Interindividual Variability of Docetaxel Pharmacokinetics and Pharmacodynamics in Asians Through Phenotyping and Genotyping StrategiesJournal of Clinical Oncology, 2002
- Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay TechniquesThe Journal of Clinical Pharmacology, 2002
- THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS*Drug Metabolism Reviews, 2000
- Auditory and electroencephalographic effects of midazolam and α‐hydroxy‐midazolam in healthy subjectsBritish Journal of Clinical Pharmacology, 2000
- IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3AAnnual Review of Pharmacology and Toxicology, 1998
- Sedation for EndoscopyJournal of Gastroenterology and Hepatology, 1996
- The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.British Journal of Clinical Pharmacology, 1995
- Noninvasive tests of CYP3A enzymesPharmacogenetics, 1994
- Midazolam A Review of its Pharmacological Properties and Therapeutic UseDrugs, 1984
- Maintenance-Dose Prediction Based on a Single Determination of Concentration: General Applicability to Two-Compartment Drugs with Reference to LithiumJournal of Pharmaceutical Sciences, 1983